Flu Vaccine Jab Can Halve Cardiac Risk

Source: Daily Mail (10/28/12)

"The flu vaccine provided an approximate 50% reduction in the risk of a heart attack or stroke compared with a placebo after one year of follow-up."

The flu jab may ward off heart attacks as well as offering protection from the infectious disease, according to a study.

Researchers found that the jab can reduce the risk of a heart attack by 50% and cardiac deaths by 40%.

They said the influenza vaccine could be an important treatment for maintaining heart health and protecting against cardiovascular events, such as strokes and heart attacks.

Cardiologist Jacob Udell and his team looked at published clinical trials on the subject dating back to the 1960s.

"For those who had the flu shot, there was a pretty strong risk reduction," he said. . .View Full Article

Analyst Likes Co. Developing Immuno-oncology Drugs
Source: Dr. Matthew Keller (06/10/2025)

There are multiple reasons to be bullish on this undervalued stock with significant potential upside, noted an H.C. Wainwright & Co. report.

New RA Drug Shown to Work, Be Safe
Source: Dr. Martin Fan (06/10/2025)

"Efficacy at six months represented a 'best case' scenario, in our view," and "safety was very favorable," noted a Wedbush report.

Biotech Firm Unveils Diabetes Breakthrough in Canada
Source: Streetwise Reports (06/10/2025)

Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) advanced its Cell Pouch device in Canada with insulin-free outcomes in all trial patients and a CA$6 target price from analysts. Read more to find out how expert advisors, international funding, and a next-gen clinical pipeline could reshape treatment for type 1 diabetes.

Phase 2b Trial Data on Treatment for Inflammation Due Soon
Source: Dr. Jonathan Aschoff (06/09/2025)

These results are expected to be favorable based on positive results of a recent interim study, noted a ROTH Capital Partners report.

Biotech Co. Reaches MS Clinical Program Milestones
Source: Jason Kolbert (06/09/2025)

These include release of additional Phase 2 trial data and completion of enrollment for two separate Phase 3 studies, noted a D. Boral Capital report.